Trial Profile
A Phase 2, Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Contezolid Acefosamil Compared to Linezolid Administered Intravenously and Orally to Adult Subjects With Acute Bacterial Skin and Skin Structure Infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2022
Price :
$35
*
At a glance
- Drugs Contezolid-acefosamil (Primary) ; Contezolid-acefosamil (Primary) ; Linezolid; Linezolid
- Indications Cellulitis; Erysipelas; Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections; Vancomycin-resistant enterococcal infections; Wound infections
- Focus Therapeutic Use
- Sponsors MicuRx Pharmaceuticals
- 13 Jul 2020 Status changed from recruiting to completed.
- 09 Sep 2019 Primary endpoint has been met. (Early clinical response in the ITT population)
- 09 Sep 2019 Top-line results published in the MicuRx Pharmaceuticals Media Release